New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
11:21 EDTLXK, SHPG, CROX, CMG, INO, VMW, PSEC, IRBT, ATHNOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
News For INO;SHPG;IRBT;CMG;LXK;PSEC;CROX;ATHN;VMW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2015
08:08 EDTINOInovio says HPV Immunotherapy activates robust in vivo T cell responses
Inovio Pharmaceuticals announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. INO-3112, an active immunotherapy that targets HPV 16 and 18 and simultaneously expresses IL-12, is designed to activate in vivo immune responses to antigens from high risk HPV types and eliminate precancerous and cancerous cells displaying these antigens. The magnitude and characteristics of these interim immune response data mirror immune responses previously observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints, the company said. The data, which are T cell measurements from the first four treated patients of this phase I/IIa study, are being presented today at the World Vaccine Congress 2015 by Inovio COO, Dr. Niranjan Sardesai.
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
19:46 EDTINOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee (APOG), up 6.4%... Pier 1 Imports (PIR), up 4.4%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 5.6% after being selected by DARPA to lead $45M Ebola prevention program. DOWN AFTER EARNINGS: Alcoa (AA), down 3.5%... Bed Bath & Beyond (BBBY), down 3.5%. ALSO LOWER: Zynga (ZNGA), down 10.3% after announcing CEO transition... Memorial Production (MEMP), down 2.9% after filing to sell 4.6M common units owned by MRD Holdco... Regulus (RGLS), down 2.2% after filing to sell 3.3M shares for Isis Pharmaceuticals.
16:12 EDTIRBTRed Mountain Capital reports 5.1% stake in iRobot
Subscribe for More Information
09:20 EDTINOOn The Fly: Pre-market Movers
Subscribe for More Information
06:06 EDTINOInovio selected by DARPA to lead $45M Ebola prevention program
Subscribe for More Information
April 7, 2015
16:55 EDTLXKXerox upgraded to Buy ahead of Q1 results at Citigroup
Subscribe for More Information
12:58 EDTATHNOn The Fly: Midday Wrap
Subscribe for More Information
10:19 EDTATHNHigh option volume stocks
Subscribe for More Information
10:17 EDTATHNathenahealth April volatility increases on wide price movement
athenahealth April weekly call option implied volatility is at 46, April is at 45, May is at 35, June is at 32; compared to its 26-week average of 38 according to Track Data, suggesting decreasing price movement.
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
09:52 EDTATHNEinhorn reiterates short thesis on athenahealth at conference
Subscribe for More Information
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
05:57 EDTCMGStocks with implied volatility above IV index mean; CMG DDD
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
April 6, 2015
10:02 EDTVMWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:09 EDTSHPGShire says will defend patents 'vigorously' after Hayman petitions
Subscribe for More Information
06:35 EDTVMWVMware upgraded to Buy from Neutral at Nomura
Nomura upgraded VMware to Buy with a $95 price target following favorable survey results. The firm's Q1 survey came in slightly ahead of plan and believes the Street is too cautious on shares, which could serve as a positive catalyst for shares. Separately, Nomura said the upcoming end of Windows Server 2003 in July could be an incremental catalyst as replacement servers will likely be virtualized.
05:43 EDTVMWVMware upgraded to Buy from Neutral at Nomura
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use